Careers  |  Sign In  |  Register

Latest in Neurology & Neurosurgery

Myriad Genetics, Inc. is discontinuing development of tarenflurbil, also known as Flurizan, after the investigational treatment for Alzheimer's disease failed to achieve significance on the co-primary endpoints - cognition and activities of daily living, of a Phase III trial. From our partners at...
Rasagiline 1 mg tablets slow the progression of Parkinson's disease, according to Phase III trial data. From our partners at VerusMed Sponsored by The Doctor's Channel
The FDA has expanded indications for methylphenidate (Concerta) extended-release tablets to include adults aged 18 to 65 with ADHD. For more information visit: FDA Sponsored by The Doctor's Channel